General Information of Drug Combination (ID: DCVNG29)

Drug Combination Name
Spironolactone Ginsenoside Rb1
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Spironolactone   DM2AQ5N Ginsenoside Rb1   DMF70AB
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 5.76
Bliss Independence Score: 5.76
Loewe Additivity Score: 18.75
LHighest Single Agent (HSA) Score: 18.77

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Spironolactone
Disease Entry ICD 11 Status REF
Chronic heart failure BD1Z Approved [2]
Congestive heart failure BD10 Approved [3]
Edema MG29 Approved [2]
Hyperaldosteronism 5A72 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [4]
Spironolactone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mineralocorticoid receptor (MR) TT26PHO MCR_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Spironolactone Interacts with 9 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [6]
Natriuretic peptides A (NPPA) OTMQNTNX ANF_HUMAN Decreases Expression [7]
Collagen alpha-1(III) chain (COL3A1) OTT1EMLM CO3A1_HUMAN Decreases Expression [7]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Decreases Expression [8]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [9]
Myb-related protein A (MYBL1) OTBJMC2P MYBA_HUMAN Increases Expression [10]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Decreases Expression [7]
Protein GREB1 (GREB1) OTU6ZA26 GREB1_HUMAN Increases Expression [10]
Renin (REN) OT52GZR2 RENI_HUMAN Decreases Response To Substance [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)
Ginsenoside Rb1 Interacts with 23 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-glucosidase (bglA) DEUO7V8 A0A509DD13_9STRE Metabolism [12]
Beta-glucosidase (bglA) DE4LKZ9 A0A3D1ZWL4_9BIFI Metabolism [12]
Beta-glucosidase (bglA) DEM6GYO A0A351PC96_9FIRM Metabolism [13], [12]
Beta-glucosidase (bglA) DE9N4OU C6WCL5_ACTMD Metabolism [14]
Beta-glucosidase (bglA) DERPJZ6 A0A4Q4LS82_BIFAN Metabolism [15]
Beta-glucosidase (bglA) DEVLXCG R7LVY8_9FUSO Metabolism [12]
Beta-glucosidase (bglA) DEUQTKA A0A249DCH3_LACRH Metabolism [15]
Beta-glucosidase (bglA) DEXRUS1 A0A267WL33_9BIFI Metabolism [16]
Beta-glucosidase (bglA) DERX7ML A0A3B8TKP6_9FIRM Metabolism [16]
Beta-glucosidase (bglA) DEOHI3U A0A0P0FEZ9_BACT4 Metabolism [16]
Beta-glucosidase (bglA) DE46IH1 A0A1T4QCU7_9PROT Metabolism [17]
Beta-glucosidase (bglA) DEE8WXK A0A076JJU4_BIFAD Metabolism [16]
Beta-glucosidase (bglA) DECBSVP A0A126SWK8_9BIFI Metabolism [16]
Beta-glucosidase (bglA) DEAVLU4 BGLFU_BIFBR Metabolism [16]
Beta-glucosidase (bglA) DEPBQES BGLS_BUTFI Metabolism [16]
Beta-glucosidase (bglA) DEGVUWH A0A174JG46_9FIRM Metabolism [16]
Beta-glucosidase (bglA) DEE8RS0 A0A174GPV4_9FIRM Metabolism [16]
Beta-glucosidase (bglA) DEC0M8H A0A174ZK85_9FIRM Metabolism [16]
Beta-glucosidase (bglA) DE2OMS0 A0A173UNF6_9FIRM Metabolism [16]
Beta-glucosidase (bglA) DEPUNVR A0A395V8H8_9FIRM Metabolism [16]
Beta-glucosidase (bglA) DEX7SAW A0A3R6A2W5_9FIRM Metabolism [16]
Beta-glucosidase (bglA) DEE3I1P A0A412BAD0_9FIRM Metabolism [16]
Beta-glucosidase (bglA) DEASJG5 A5ZMW4_9FIRM Metabolism [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 DME(s)
Ginsenoside Rb1 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Potassium voltage-gated channel subfamily E member 1 (KCNE1) OTZNQUW9 KCNE1_HUMAN Increases Expression [18]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Spironolactone FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2875).
4 Spironolactone in Covid-19 Induced ARDS
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
7 Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001 Apr;37(5):1228-33. doi: 10.1016/s0735-1097(01)01116-0.
8 Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res. 2002;25(4):260-4. doi: 10.1159/000066348.
9 Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells. Toxicology. 2011 Jul 11;285(1-2):18-24. doi: 10.1016/j.tox.2011.03.015. Epub 2011 Apr 1.
10 A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
11 Clinical and biochemical effects of spironolactone administered once daily in primary hypertension. Multicenter Sweden study. Hypertension. 1980 Sep-Oct;2(5):672-9. doi: 10.1161/01.hyp.2.5.672.
12 Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
13 Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol. 1998 Oct;50(10):1155-60.
14 Characterization of the ginsenoside-transforming recombinant beta-glucosidase from Actinosynnema mirum and bioconversion of major ginsenosides into minor ginsenosides. Appl Microbiol Biotechnol. 2013 Jan;97(2):649-59.
15 Fermentation of protopanaxadiol type ginsenosides (PD) with probiotic Bifidobacterium lactis and Lactobacillus rhamnosus. Appl Microbiol Biotechnol. 2017 Jul;101(13):5427-5437.
16 Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
17 Genus Enhydrobacter Staley et al. 1987 should be recognized as a member of the family Rhodospirillaceae within the class Alphaproteobacteria. Microbiol Immunol. 2012 Jan;56(1):21-6.
18 Ginsenosides may enhance the functionality of human embryonic stem cell-derived cardiomyocytes in vitro. Reprod Sci. 2014 Oct;21(10):1312-8. doi: 10.1177/1933719114525269. Epub 2014 Mar 10.